Streamlining vendor oversight: Monitoring site-level and laboratory performance across multiple oncology trials
The challenge: Maintaining clinical trial timelines dependent on vendor performance
A global biotechnology company with seven clinical-phase programs approached QuartzBio with a challenge shared by many organizations in the industry -- overall assessment of clinical trial vendors and sites was time-consuming and unreliable, given global site footprints, complex sample lifecycles, and inconsistent naming across sites and vendors.
Tasked with preparing regular executive summaries, the company’s clinical and biomarker operations teams were spending significant time deriving trial-wide key performance indicators (KPIs), lacking visibility into vendor performance – and challenged to translate current experience into future study Read More →
Title: Critical Biomarker Operations KPIs Across Clinical Portfolios
Duration: 30 minutes
Clinical and biomarker operations teams face challenges with global site footprints, complex sample lifecycles, and inconsistent naming across sites and vendors.
Watch our webinar to learn how teams are monitoring key performance indicators (KPIs) for clinical sample status, quality, and data availability – on-study and across clinical portfolios.
Adam S. Brown, PhD of QuartzBio will share how teams are assessing key deliverables:
- Site performance including collection rates, collection quality metrics, and Read More →
February 18, 2022 -- At our first in-person conference in over a year, the QuartzBio team had a chance to connect with biomarker operations and clinical operations teams in Orlando, Florida, earlier this month.
In the “Clinical Biomarkers Operations and Innovation” track, we joined discussions on the latest approaches to structuring clinical sample management to best support complex biomarker-informed clinical trials.
Here are three recurring challenges we heard about at SCOPE this year:Read More →
February 9, 2022 — Clinical operations leaders use the QuartzBio® virtual Sample Inventory Management (vSIM) solution to maintain robust visibility across sample collection and processing status, consent status, and sample and derivative quality information.
Traditionally, generating these reports is frustratingly time-consuming – often involving spreadsheets that attempt to manually link key information from the EDC, central labs, testing labs, and biorepositories to illuminate critical information like discrepancies or missed collections.
The QuartzBio team has identified six critical on-study reports that our clients prioritize as absolutely required for effective sample and biomarker operations.Read More →